TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers mapped immune aging using blood-cell data from 2,609 adults and found that a profile weighted toward granzyme B-producing cells was associated with greater later risks of death and several chronic diseases. The findings are not a diagnostic test: researchers say a simpler blood test is in development, and the results do not establish that the cell pattern causes disease.
Researchers from Washington University School of Medicine in St. Louis, Nationwide Children’s Hospital and King’s College London have mapped differences in how immune systems age, linking a blood profile weighted toward granzyme B-producing immune cells with higher later risks of death and chronic disease. The study, published Oct. 9 in Immunity, suggests immune aging may provide information about future health beyond a person’s age in years, but it does not establish a diagnosis or prove that the cell pattern causes disease.
The team analyzed about 12.4 million immune cells from blood samples of 2,609 mainly healthy adults, ages 20 to over 90, across eight cohorts in North America, the United Kingdom, Asia and Australia. Younger participants generally had more naive immune cells, which have not yet encountered specific pathogens. Older participants showed greater variation, including differences in the abundance of cells associated with inflammation.
Researchers organized participants along a spectrum using the balance between two types of effector memory CD8 T cells: those producing granzyme B and those producing granzyme K. Granzyme B cells can directly destroy target cells; granzyme K cells are less studied and may help signal for additional immune responses, according to the report.
To examine future health outcomes, the researchers developed a model using a smaller dataset with CD8 T-cell counts and blood-protein measurements, then applied it to baseline protein data for 50,000 UK Biobank participants. The biobank had medical histories covering up to 15 years. Participants classified as more granzyme B-dominant at baseline were more likely to die about a decade later and more likely to develop conditions including type 2 diabetes, hypertension, liver disease and renal failure. The source does not provide absolute risk estimates for these outcomes.
A Blood Signal Before Diagnosis
The findings point to a possible way of identifying differences in health risk that are not captured by chronological age alone. If the association is confirmed and translated into a reliable test, clinicians could potentially use immune-cell patterns to identify people who may need closer follow-up before symptoms lead to a diagnosis.
That possibility remains prospective. The study identifies an association between a modeled immune profile and later outcomes; it does not show that changing the balance of these cells would prevent chronic disease, or that screening based on the profile improves health. The research team says its current work is aimed at a simpler blood test that could be processed with standard equipment. Until that test is developed and evaluated, the map is a research tool rather than an established clinical screening method.
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Map
The study addresses why people of the same age can have different health outcomes. The researchers describe immune aging as a spectrum rather than a uniform decline: some older adults retain more resilient immune profiles, while others show patterns associated with inflammation. The balance between granzyme-producing CD8 T cells was used to place participants on that spectrum.
The analysis combined cell-level work in several cohorts with long-term health records from the UK Biobank. Because the biobank did not include direct counts of the relevant CD8 T cells, the researchers used a separate dataset to model the blood-protein patterns associated with each cell type and applied that model to the biobank’s baseline samples. This distinction matters: the large outcome analysis relied on a model of immune position, not direct cell counts for every biobank participant.
“There are clues in the blood that can tell us whether someone is on a healthy or unhealthy aging trajectory.”
— Maxim N. Artyomov, co-corresponding author and professor at Washington University School of Medicine
As an affiliate, we earn on qualifying purchases.
Limits of the Risk Estimate
The reported results do not show how much an individual’s absolute risk changes, and the source does not provide the detailed risk estimates or thresholds needed to interpret a result for a particular person. It also remains unclear how well the model would perform in routine clinical settings or across populations beyond the cohorts studied.
The association does not establish that granzyme B-producing cells cause later disease or death. Other factors could contribute to both the immune profile and health outcomes. The research report describes a model applied to UK Biobank protein samples, rather than a validated test that directly measures and reports immune-aging risk. The proposed diagnostic’s accuracy, cost, and clinical usefulness have not yet been established.
As an affiliate, we earn on qualifying purchases.
Testing the Proposed Blood Test
Artyomov and his lab are adapting the research into a blood test intended to use standard equipment. The source does not give a release date or report that the test is available to patients. Before it could guide care, researchers would need to establish how consistently it measures the immune profile, how accurately that profile predicts outcomes, and whether using the result leads to better decisions or health outcomes.
For now, the next step is further development and evaluation of the test and the immune-aging model. The study offers a map of associations that may help researchers investigate risk; it does not change current diagnostic standards or establish a routine screening recommendation.
As an affiliate, we earn on qualifying purchases.
Key Questions
What does the immune-aging map measure?
It places immune profiles along a spectrum based on the balance between granzyme B-producing and granzyme K-producing CD8 T cells, using cell data and modeled blood-protein patterns.
Which health outcomes were associated with a granzyme B-heavy profile?
In the UK Biobank analysis, the profile was associated with higher later risks of death and conditions including type 2 diabetes, hypertension, liver disease and renal failure. The source does not give absolute risk estimates.
Does the study prove that the immune profile causes chronic disease?
No. The study reports an association between a modeled immune profile and later outcomes. It does not establish that the cell pattern causes disease.
Can people get this blood test now?
The source says researchers are adapting the work into a simpler test. It does not say the test is available for clinical use or provide a launch date.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
